Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Unusually active option classes on open March 15th » 09:40
03/15/23
03/15
09:40
03/15/23
09:40
FTI

TechnipFMC

$13.70 /

+ (+0.00%)

, TEVA

Teva

$8.92 /

+ (+0.00%)

, EWG

iShares MSCI Germany

$27.45 /

+ (+0.00%)

, SHEL

Shell

$59.39 /

+ (+0.00%)

, UUP

PowerShares DB US Dollar Index Up

$28.09 /

+ (+0.00%)

, IWM

iShares Trust Russell 2000 Index Fund

$176.59 /

+ (+0.00%)

, VALE

Vale

$15.94 /

+ (+0.00%)

, GLD

SPDR Gold Shares

$176.85 /

+ (+0.00%)

, UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$5.77 /

+0.035 (+0.61%)

Unusual total active…

Unusual total active option classes on open include: FMC Technologies (FTI), Global X Uranium (URA), Teva (TEVA), iShares Germany (EWG), Shell PLC (SHEL), PowerShares DB US Dollar Index Bullish Fund (UUP), iShares Russell 2000 ETF (IWM), Vale (VALE), SPDR Gold Trust (GLD), and ProShares Ultra VIX Short Term Futures (UVXY).

ShowHide Related Items >><<
VALE Vale
$15.94 /

+ (+0.00%)

TEVA Teva
$8.92 /

+ (+0.00%)

SHEL Shell
$59.39 /

+ (+0.00%)

IWM iShares Trust Russell 2000 Index Fund
$176.59 /

+ (+0.00%)

GLD SPDR Gold Shares
$176.85 /

+ (+0.00%)

FTI TechnipFMC
$13.70 /

+ (+0.00%)

FTI TechnipFMC
$13.70 /

+ (+0.00%)

02/28/23 Citi
TechnipFMC price target raised to $20 from $18 at Citi
02/27/23 Barclays
TechnipFMC price target raised to $20 from $14 at Barclays
02/24/23 TD Cowen
TechnipFMC price target raised to $20 from $17 at Cowen
02/24/23 BTIG
TechnipFMC price target raised to $18 from $15 at BTIG
TEVA Teva
$8.92 /

+ (+0.00%)

03/13/23 RBC Capital
Teva's CP trial failure may add some risk for Neurocrine, says RBC Capital
02/14/23 BofA
Axsome facing Auvelity IP challenge 'not a surprise,' says BofA
02/09/23 Barclays
Teva price target raised to $14 from $13 at Barclays
01/23/23 Piper Sandler
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
EWG iShares MSCI Germany
$27.45 /

+ (+0.00%)

SHEL Shell
$59.39 /

+ (+0.00%)

02/28/23 AlphaValue/Baader
Shell upgraded to Add from Reduce at AlphaValue/Baader
02/26/23 Goldman Sachs
Shell upgraded to Buy from Neutral at Goldman Sachs
02/24/23 JPMorgan
Shell price target raised to 3,000 GBp from 2,950 GBp at JPMorgan
02/17/23 Berenberg
Shell price target raised to 3,000 GBp from 2,900 GBp at Berenberg
UUP PowerShares DB US Dollar Index Up
$28.09 /

+ (+0.00%)

IWM iShares Trust Russell 2000 Index Fund
$176.59 /

+ (+0.00%)

VALE Vale
$15.94 /

+ (+0.00%)

02/09/23 JPMorgan
Vale downgraded to Neutral from Overweight at JPMorgan
02/06/23 RBC Capital
RBC downgrades Vale, says shares 'moved past fair value'
02/06/23 RBC Capital
Vale downgraded to Sector Perform from Outperform at RBC Capital
12/09/22 Morgan Stanley
Vale upgraded to Overweight from Equal Weight at Morgan Stanley
GLD SPDR Gold Shares
$176.85 /

+ (+0.00%)

UVXY ProShares Trust Ultra VIX Short Term Futures ETF
$5.77 /

+0.035 (+0.61%)

TEVA Teva
$8.92 /

+ (+0.00%)

SHEL Shell
$59.39 /

+ (+0.00%)

FTI TechnipFMC
$13.70 /

+ (+0.00%)

VALE Vale
$15.94 /

+ (+0.00%)

TEVA Teva
$8.92 /

+ (+0.00%)

SHEL Shell
$59.39 /

+ (+0.00%)

VALE Vale
$15.94 /

+ (+0.00%)

TEVA Teva
$8.92 /

+ (+0.00%)

SHEL Shell
$59.39 /

+ (+0.00%)

FTI TechnipFMC
$13.70 /

+ (+0.00%)

VALE Vale
$15.94 /

+ (+0.00%)

UVXY ProShares Trust Ultra VIX Short Term Futures ETF
$5.77 /

+0.035 (+0.61%)

UUP PowerShares DB US Dollar Index Up
$28.09 /

+ (+0.00%)

TEVA Teva
$8.92 /

+ (+0.00%)

SHEL Shell
$59.39 /

+ (+0.00%)

IWM iShares Trust Russell 2000 Index Fund
$176.59 /

+ (+0.00%)

GLD SPDR Gold Shares
$176.85 /

+ (+0.00%)

EWG iShares MSCI Germany
$27.45 /

+ (+0.00%)

IWM iShares Trust Russell 2000 Index Fund
$176.59 /

+ (+0.00%)

Recommendations
Teva's CP trial failure may add some risk for Neurocrine, says RBC Capital » 09:37
03/13/23
03/13
09:37
03/13/23
09:37
NBIX

Neurocrine

$95.84 /

-1.385 (-1.42%)

, TEVA

Teva

$9.13 /

-0.2 (-2.14%)

RBC Capital notes that…

RBC Capital notes that the clinicaltrials.gov listing for an open-label study of Teva's (TEVA) Austedo in cerebral palsy was just updated to indicate that it has been terminated as the main phase 3 study for that drug in cerebral palsy had failed. The analyst also points out that Neurocrine (NBIX), as part of its life cycle strategy, has been conducting phase 3 studies for Ingrezza in additional indications beyond TD and Huntington's, namely schizophrenia and cerebral palsy, and said that Austedo, which is on the market for TD and Huntington's, "has a nearly identical mechanism to Ingrezza." Teva's study failure could increase the risk for Neurocrine's cerebral palsy trial and may add incremental risk to the CP indication for Neurocrine, though the latter's recent trial adjustments "could still preserve some potential" for it to succeed in phase 3, said the firm, which maintains a Sector Perform rating and $110 price target on Neurocrine shares.

ShowHide Related Items >><<
TEVA Teva
$9.13 /

-0.2 (-2.14%)

NBIX Neurocrine
$95.84 /

-1.385 (-1.42%)

NBIX Neurocrine
$95.84 /

-1.385 (-1.42%)

03/03/23 Evercore ISI
Neurocrine upgraded to Outperform at Evercore with stock 25% off highs
03/03/23 Evercore ISI
Neurocrine upgraded to Outperform from In Line at Evercore ISI
02/07/23 RBC Capital
Neurocrine price target lowered to $110 from $122 at RBC Capital
02/07/23 Wells Fargo
Neurocrine price target lowered to $115 from $120 at Wells Fargo
TEVA Teva
$9.13 /

-0.2 (-2.14%)

02/14/23 BofA
Axsome facing Auvelity IP challenge 'not a surprise,' says BofA
02/09/23 Barclays
Teva price target raised to $14 from $13 at Barclays
01/23/23 Piper Sandler
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
01/19/23 Jefferies
Teva downgraded to Hold from Buy at Jefferies
TEVA Teva
$9.13 /

-0.2 (-2.14%)

NBIX Neurocrine
$95.84 /

-1.385 (-1.42%)

TEVA Teva
$9.13 /

-0.2 (-2.14%)

TEVA Teva
$9.13 /

-0.2 (-2.14%)

NBIX Neurocrine
$95.84 /

-1.385 (-1.42%)

TEVA Teva
$9.13 /

-0.2 (-2.14%)

Hot Stocks
Teva and NATCO Pharma launch additional strengths for generic Revlimid » 08:19
03/09/23
03/09
08:19
03/09/23
08:19
TEVA

Teva

$9.66 /

+0.215 (+2.28%)

Teva Pharmaceuticals and…

Teva Pharmaceuticals and NATCO Pharma announced the launch of additional strengths for the generic version of Revlimid, lenalidomide capsules, in 2.5 mg, and 20 mg strengths, in the United States. The companies have launched four other strengths of the product in March 2022 in the US market. With today's launch the companies made available all the strengths of lenalidomide in the US market. Teva's lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment. Please see the below "What are lenalidomide capsules?" section for more information. "The launch of additional strengths for the generic version of Revlimid in the U.S. enhances access to an important treatment option for patients, and further demonstrates Teva's commitment to making generic drugs available to the patients who need them," said Christine Baeder, SVP, Chief Operating Officer, US Generics and Biosimilars, at Teva USA. With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market, and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the U.S. Currently, 1 in 12 generic prescriptions dispensed in the U.S. is filled with a Teva generic product. Revlimid had annual sales of $2.9B as of January according to IQVIA data.

ShowHide Related Items >><<
TEVA Teva
$9.66 /

+0.215 (+2.28%)

TEVA Teva
$9.66 /

+0.215 (+2.28%)

02/14/23 BofA
Axsome facing Auvelity IP challenge 'not a surprise,' says BofA
02/09/23 Barclays
Teva price target raised to $14 from $13 at Barclays
01/23/23 Piper Sandler
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
01/19/23 Jefferies
Teva downgraded to Hold from Buy at Jefferies
TEVA Teva
$9.66 /

+0.215 (+2.28%)

TEVA Teva
$9.66 /

+0.215 (+2.28%)

TEVA Teva
$9.66 /

+0.215 (+2.28%)

TEVA Teva
$9.66 /

+0.215 (+2.28%)

Options
Teva call volume above normal and directionally bullish » 14:45
03/03/23
03/03
14:45
03/03/23
14:45
TEVA

Teva

$10.06 /

+0.095 (+0.95%)

Bullish option flow…

Bullish option flow detected in Teva with 16,535 calls trading, 1.5x expected, and implied vol increasing almost 17 points to 53.31%. Mar-23 11 calls and 3/24 weekly 10.5 calls are the most active options, with total volume in those strikes near 4,700 contracts. The Put/Call Ratio is 0.26. Earnings are expected on May 2nd.

ShowHide Related Items >><<
TEVA Teva
$10.06 /

+0.095 (+0.95%)

TEVA Teva
$10.06 /

+0.095 (+0.95%)

02/14/23 BofA
Axsome facing Auvelity IP challenge 'not a surprise,' says BofA
02/09/23 Barclays
Teva price target raised to $14 from $13 at Barclays
01/23/23 Piper Sandler
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
01/19/23 Jefferies
Teva downgraded to Hold from Buy at Jefferies
TEVA Teva
$10.06 /

+0.095 (+0.95%)

TEVA Teva
$10.06 /

+0.095 (+0.95%)

TEVA Teva
$10.06 /

+0.095 (+0.95%)

TEVA Teva
$10.06 /

+0.095 (+0.95%)

Over a month ago
Hot Stocks
Teva announces print publication of IMPACT-TD Scale » 08:11
02/23/23
02/23
08:11
02/23/23
08:11
TEVA

Teva

$9.96 /

+0.04 (+0.40%)

Teva Pharmaceuticals, a…

Teva Pharmaceuticals, a U.S. affiliate of Teva, announced the print publication of the IMPACT-TD Scale, a standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia, or TD, on different aspects of a patient's daily functioning. IMPACT-TD categorizes the consequences of TD symptoms into multiple functional domains: social, psychological/psychiatric, physical and vocational/educational/recreational. The scale was developed to collect insights from not only patients but also family members, caregivers and providers, to help foster more productive dialogue and provide the most comprehensive understanding of the impact of TD.

ShowHide Related Items >><<
TEVA Teva
$9.96 /

+0.04 (+0.40%)

TEVA Teva
$9.96 /

+0.04 (+0.40%)

02/14/23 BofA
Axsome facing Auvelity IP challenge 'not a surprise,' says BofA
02/09/23 Barclays
Teva price target raised to $14 from $13 at Barclays
01/23/23 Piper Sandler
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
01/19/23 Jefferies
Teva downgraded to Hold from Buy at Jefferies
TEVA Teva
$9.96 /

+0.04 (+0.40%)

TEVA Teva
$9.96 /

+0.04 (+0.40%)

TEVA Teva
$9.96 /

+0.04 (+0.40%)

TEVA Teva
$9.96 /

+0.04 (+0.40%)

Hot Stocks
Teva announces FDA approval of AUSTEDO XR tablets » 16:57
02/17/23
02/17
16:57
02/17/23
16:57
TEVA

Teva

$10.06 /

-0.035 (-0.35%)

Teva Pharmaceuticals…

Teva Pharmaceuticals announced that the U.S. Food and Drug Administration has approved AUSTEDO XR extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington's disease. AUSTEDO XR is an additional formulation of the currently marketed twice-daily AUSTEDO. "The approval of AUSTEDO XR is a reflection of our ongoing innovation for people living with TD and HD chorea," said Eric Hughes, MD, PhD, Executive Vice President of R&D and Chief Medical Officer at Teva. "For some patients living with TD and HD, treatment adherence can be a challenge that this new once-daily dosing option can help to address." Once-daily AUSTEDO XR has been shown to be therapeutically equivalent to the twice-daily formulation, providing another effective treatment choice. It will be available in three extended-release tablet strengths - 6 mg, 12 mg, and 24 mg - and can be taken with or without food. The new tablet strengths provide an updated regimen which may result in a decreased pill count for patients compared to the twice-daily formulation.

ShowHide Related Items >><<
TEVA Teva
$10.06 /

-0.035 (-0.35%)

TEVA Teva
$10.06 /

-0.035 (-0.35%)

02/14/23 BofA
Axsome facing Auvelity IP challenge 'not a surprise,' says BofA
02/09/23 Barclays
Teva price target raised to $14 from $13 at Barclays
01/23/23 Piper Sandler
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
01/19/23 Jefferies
Teva downgraded to Hold from Buy at Jefferies
TEVA Teva
$10.06 /

-0.035 (-0.35%)

TEVA Teva
$10.06 /

-0.035 (-0.35%)

TEVA Teva
$10.06 /

-0.035 (-0.35%)

TEVA Teva
$10.06 /

-0.035 (-0.35%)

Hot Stocks
Teva Neuroscience granted FDA approval for amended Austedo XR NDA » 14:57
02/17/23
02/17
14:57
02/17/23
14:57
TEVA

Teva

$10.04 /

-0.055 (-0.54%)

A letter posted to the…

A letter posted to the site of the FDA indicates that the agency approved the new drug application, or NDA, submitted by Teva Neuroscience, as amended, for the use of Austedo XR 6, 12, and 24 mg tablets for the treatment of chorea associated with Huntington's disease and tardive dyskinesia. Reference Link

ShowHide Related Items >><<
TEVA Teva
$10.04 /

-0.055 (-0.54%)

TEVA Teva
$10.04 /

-0.055 (-0.54%)

02/14/23 BofA
Axsome facing Auvelity IP challenge 'not a surprise,' says BofA
02/09/23 Barclays
Teva price target raised to $14 from $13 at Barclays
01/23/23 Piper Sandler
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
01/19/23 Jefferies
Teva downgraded to Hold from Buy at Jefferies
TEVA Teva
$10.04 /

-0.055 (-0.54%)

TEVA Teva
$10.04 /

-0.055 (-0.54%)

TEVA Teva
$10.04 /

-0.055 (-0.54%)

TEVA Teva
$10.04 /

-0.055 (-0.54%)

Recommendations
Axsome facing Auvelity IP challenge 'not a surprise,' says BofA » 07:53
02/14/23
02/14
07:53
02/14/23
07:53
AXSM

Axsome Therapeutics

$62.08 /

-0.9 (-1.43%)

, TEVA

Teva

$10.30 /

+0.04 (+0.39%)

After Axsome Therapeutics…

After Axsome Therapeutics (AXSM) disclosed yesterday that Teva (TEVA) submitted a Paragraph 4 patent challenge against Auvelity for MDD, BofA analyst Jason Gerberry said the IP challenge "comes as expected" and is not a surprise since Auvelity is not a new chemical entity and "lacked the regulatory exclusivity necessary to shield the drug from early IP challenge." The "only surprise" is that the challenge came so quickly, happening only about four months post Auvelity's commercial launch, according to the firm. BofA reiterates an Underperform rating and $52 price target on Axsome as it expects Auvelity's MDD launch to fall short of consensus expectations.

ShowHide Related Items >><<
TEVA Teva
$10.30 /

+0.04 (+0.39%)

AXSM Axsome Therapeutics
$62.08 /

-0.9 (-1.43%)

AXSM Axsome Therapeutics
$62.08 /

-0.9 (-1.43%)

01/30/23 Mizuho
Axsome Therapeutics price target raised to $86 from $80 at Mizuho
01/05/23 Piper Sandler
Axsome Therapeutics initiated with a Neutral at Piper Sandler
01/03/23 BTIG
Axsome Therapeutics named Top Pick for first half of 2023 at BTIG
12/23/22 BTIG
Axsome Therapeutics price target raised to $98 from $62 at BTIG
TEVA Teva
$10.30 /

+0.04 (+0.39%)

02/09/23 Barclays
Teva price target raised to $14 from $13 at Barclays
01/23/23 Piper Sandler
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
01/19/23 Jefferies
Teva downgraded to Hold from Buy at Jefferies
01/06/23 Northland
Alvotech named a top pick for 2023 at Northland
TEVA Teva
$10.30 /

+0.04 (+0.39%)

AXSM Axsome Therapeutics
$62.08 /

-0.9 (-1.43%)

TEVA Teva
$10.30 /

+0.04 (+0.39%)

TEVA Teva
$10.30 /

+0.04 (+0.39%)

AXSM Axsome Therapeutics
$62.08 /

-0.9 (-1.43%)

TEVA Teva
$10.30 /

+0.04 (+0.39%)

AXSM Axsome Therapeutics
$62.08 /

-0.9 (-1.43%)

On The Fly
What You Missed On Wall Street On Monday » 16:33
02/13/23
02/13
16:33
02/13/23
16:33
Z

Zillow

$44.84 /

+1.83 (+4.25%)

, META

Meta Platforms

$179.41 /

+5.29 (+3.04%)

, FIS

FIS

$66.02 /

-9.455 (-12.53%)

, TWLO

Twilio

$61.32 /

+1.24 (+2.06%)

, MNDY

Monday.com

$145.43 /

+13.78 (+10.47%)

, TDC

Teradata

$39.54 /

+5.3 (+15.48%)

, RKT

Rocket Companies

$8.87 /

+0.065 (+0.74%)

, CAT

Caterpillar

$248.15 /

+0.53 (+0.21%)

, FSLY

Fastly

$12.61 /

+2.735 (+27.71%)

, FIVE

Five Below

$207.01 /

+5.27 (+2.61%)

, OKTA

Okta

$75.48 /

-0.88 (-1.15%)

, ZG

Zillow Group

$44.11 /

+1.84 (+4.35%)

, MANU

Manchester United

$23.59 /

+0.09 (+0.38%)

, SFTBY

SoftBank Group

$22.15 /

-0.05 (-0.23%)

, WISH

ContextLogic

/

+

, MSFT

Microsoft

$271.21 /

+8.09 (+3.07%)

, OCUL

Ocular Therapeutix

$5.23 /

+1.355 (+34.97%)

, GTHX

G1 Therapeutics

$3.34 /

-3.805 (-53.29%)

, AXSM

Axsome Therapeutics

$62.08 /

-0.9 (-1.43%)

, ZIM

ZIM Integrated

$20.98 /

-1.485 (-6.61%)

, TEVA

Teva

$10.30 /

+0.04 (+0.39%)

, THS

TreeHouse

$48.37 /

+0.09 (+0.19%)

, CHKP

Check Point

$128.32 /

+1.09 (+0.86%)

, SHC

Sotera Health

$16.91 /

+0.11 (+0.65%)

, IAA

IAA

$43.80 /

+0.825 (+1.92%)

, RBA

Ritchie Bros.

$64.17 /

+1.13 (+1.79%)

, INTC

Intel

$28.54 /

+0.735 (+2.64%)

, IBM

IBM

$137.34 /

+1.73 (+1.28%)

, QCOM

Qualcomm

$130.79 /

+1.88 (+1.46%)

, TXN

Texas Instruments

$176.72 /

+0.97 (+0.55%)

, AVGO

Broadcom

$601.20 /

+6.825 (+1.15%)

, GFS

GlobalFoundries

$66.11 /

+1.525 (+2.36%)

Get caught up quickly on…

ShowHide Related Items >><<
ZIM ZIM Integrated
$20.98 /

-1.485 (-6.61%)

ZG Zillow Group
$44.11 /

+1.84 (+4.35%)

Z Zillow
$44.84 /

+1.83 (+4.25%)

WISH ContextLogic
/

+

TXN Texas Instruments
$176.72 /

+0.97 (+0.55%)

TWLO Twilio
$61.32 /

+1.24 (+2.06%)

THS TreeHouse
$48.37 /

+0.09 (+0.19%)

TEVA Teva
$10.30 /

+0.04 (+0.39%)

TDC Teradata
$39.54 /

+5.3 (+15.48%)

SHC Sotera Health
$16.91 /

+0.11 (+0.65%)

SFTBY SoftBank Group
$22.15 /

-0.05 (-0.23%)

RKT Rocket Companies
$8.87 /

+0.065 (+0.74%)

RBA Ritchie Bros.
$64.17 /

+1.13 (+1.79%)

QCOM Qualcomm
$130.79 /

+1.88 (+1.46%)

OKTA Okta
$75.48 /

-0.88 (-1.15%)

OCUL Ocular Therapeutix
$5.23 /

+1.355 (+34.97%)

MSFT Microsoft
$271.21 /

+8.09 (+3.07%)

MNDY Monday.com
$145.43 /

+13.78 (+10.47%)

META Meta Platforms
$179.41 /

+5.29 (+3.04%)

MANU Manchester United
$23.59 /

+0.09 (+0.38%)

INTC Intel
$28.54 /

+0.735 (+2.64%)

IBM IBM
$137.34 /

+1.73 (+1.28%)

IAA IAA
$43.80 /

+0.825 (+1.92%)

GTHX G1 Therapeutics
$3.34 /

-3.805 (-53.29%)

GFS GlobalFoundries
$66.11 /

+1.525 (+2.36%)

FSLY Fastly
$12.61 /

+2.735 (+27.71%)

FIVE Five Below
$207.01 /

+5.27 (+2.61%)

FIS FIS
$66.02 /

-9.455 (-12.53%)

CHKP Check Point
$128.32 /

+1.09 (+0.86%)

CAT Caterpillar
$248.15 /

+0.53 (+0.21%)

AXSM Axsome Therapeutics
$62.08 /

-0.9 (-1.43%)

AVGO Broadcom
$601.20 /

+6.825 (+1.15%)

Z Zillow
$44.84 /

+1.83 (+4.25%)

02/13/23 Evercore ISI
Zillow Group upgraded to Outperform at Evercore on five 'key factors'
02/13/23 Evercore ISI
Zillow Group upgraded to Outperform from In Line at Evercore ISI
02/07/23 Piper Sandler
Zillow Group price target raised to $40 from $31 at Piper Sandler
01/09/23 BofA
Zillow Group upgraded to Buy from Underperform at BofA
META Meta Platforms
$179.41 /

+5.29 (+3.04%)

02/13/23 BofA
BofA sees room for additional efficiencies at Meta
02/10/23 Tigress Financial
Meta Platforms price target raised to $285 from $260 at Tigress Financial
02/08/23 Loop Capital
Meta Platforms price target raised to $188 from $165 at Loop Capital
02/03/23 DA Davidson
Amazon.com price target raised to $134 from $114 at DA Davidson
FIS FIS
$66.02 /

-9.455 (-12.53%)

02/14/23 Credit Suisse
FIS downgraded to Neutral at Credit Suisse on disappointing FY23 outlook
02/14/23 Credit Suisse
FIS downgraded to Neutral from Outperform at Credit Suisse
02/14/23 Baird
FIS price target lowered to $80 from $84 at Baird
02/14/23 Barclays
FIS price target lowered to $68 from $73 at Barclays
TWLO Twilio
$61.32 /

+1.24 (+2.06%)

02/13/23 Jefferies
Twilio restructuring shifts focus into earnings, says Jefferies
02/13/23 Stifel
Twilio price target raised to $60 from $45 at Stifel
02/13/23 Baird
Baird positive on Twilio's restructuring plans, cost reductions
01/17/23 Piper Sandler
Twilio price target lowered to $69 from $79 at Piper Sandler
MNDY Monday.com
$145.43 /

+13.78 (+10.47%)

02/14/23 Canaccord
Monday.com price target raised to $160 from $120 at Canaccord
02/14/23 TD Cowen
Monday.com price target raised to $175 from $165
02/14/23 Credit Suisse
Monday.com price target raised to $170 from $140 at Credit Suisse
02/14/23 KeyBanc
Monday.com price target raised to $180 from $156 at KeyBanc
TDC Teradata
$39.54 /

+5.3 (+15.48%)

02/14/23 TD Cowen
Teradata price target raised to $40 from $36 at Cowen
02/14/23 Barclays
Teradata price target raised to $35 from $33 at Barclays
01/26/23 Guggenheim
Teradata initiated with a Neutral at Guggenheim
12/12/22 RBC Capital
Coupa Software upgraded to Sector Perform from Underperform at RBC Capital
RKT Rocket Companies
$8.87 /

+0.065 (+0.74%)

01/10/23 JPMorgan
Rocket Companies price target raised to $8 from $7 at JPMorgan
01/09/23 Credit Suisse
Rocket Companies downgraded to Underperform from Neutral at Credit Suisse
01/06/23 Barclays
Rocket Companies price target raised to $6 from $4.50 at Barclays
11/16/22 Argus
Rocket Companies cut to Sell at Argus on decline in mortgage originations
CAT Caterpillar
$248.15 /

+0.53 (+0.21%)

02/13/23 Baird
Caterpillar downgraded to Neutral from Outperform at Baird
02/07/23 BMO Capital
Caterpillar price target raised to $230 from $210 at BMO Capital
02/01/23 Wells Fargo
Caterpillar price target raised to $240 from $228 at Wells Fargo
02/01/23 Credit Suisse
Caterpillar price target raised to $306 from $290 at Credit Suisse
FSLY Fastly
$12.61 /

+2.735 (+27.71%)

02/13/23 BofA
Fastly double upgraded to Buy at BofA on intermediate-term potential
02/13/23 BofA
Fastly upgraded to Buy from Underperform at BofA
11/21/22 Credit Suisse
Fastly initiated with a Neutral at Credit Suisse
FIVE Five Below
$207.01 /

+5.27 (+2.61%)

02/13/23 Roth MKM
Five Below upgraded to Buy from Neutral at Roth MKM
02/10/23
Gordon Haskett upgrades Five Below to Buy on growth confidence
02/10/23
Five Below upgraded to Buy from Accumulate at Gordon Haskett
02/07/23 Barclays
Barclays sees a 'reset' in U.S. retail but 'not a recession yet'
OKTA Okta
$75.48 /

-0.88 (-1.15%)

02/14/23 Goldman Sachs
Okta initiated with a Sell at Goldman Sachs
02/13/23 BofA
BofA starts Okta at Underperform with 'no positive catalysts in sight'
02/13/23 BofA
Okta initiated with an Underperform at BofA
02/03/23 RBC Capital
Okta price target raised to $95 from $80 at RBC Capital
ZG Zillow Group
$44.11 /

+1.84 (+4.35%)

MANU Manchester United
$23.59 /

+0.09 (+0.38%)

12/09/22 Deutsche Bank
Manchester United downgraded to Hold from Buy at Deutsche Bank
11/23/22 Jefferies
Jefferies expects 'competitive process' for Manchester United
06/02/22 Deutsche Bank
Manchester United undervalued after selloff, says Deutsche Bank
03/21/22 Deutsche Bank
Manchester United upgraded on 'value disconnect' at Deutsche Bank
SFTBY SoftBank Group
$22.15 /

-0.05 (-0.23%)

12/06/22 JPMorgan
SoftBank Group downgraded to Neutral from Overweight at JPMorgan
11/29/22 Citi
SoftBank Group downgraded to Neutral from Buy at Citi
11/14/22 Jefferies
SoftBank Group downgraded to Underperform from Hold at Jefferies
10/26/22 Jefferies
SoftBank Group downgraded to Hold from Buy at Jefferies
WISH ContextLogic
/

+

12/13/22 Citi
ContextLogic initiated with a Sell at Citi
08/10/22 Credit Suisse
ContextLogic free cash flow to improve from here, says Credit Suisse
03/22/22 Loop Capital
ContextLogic cut to Hold at Loop Capital on inflation and and European exposure
03/22/22 Loop Capital
ContextLogic downgraded to Hold from Buy at Loop Capital
MSFT Microsoft
$271.21 /

+8.09 (+3.07%)

02/13/23 Morgan Stanley
Morgan Stanley sees 5 quarters of accelerating EPS growth at Microsoft after Q2
02/10/23 Roth MKM
Activision Blizzard price target lowered to $88 from $95 at Roth MKM
02/10/23 Jefferies
Jefferies positive on Alphabet AI advantages, says 'stock hit overdone'
OCUL Ocular Therapeutix
$5.23 /

+1.355 (+34.97%)

02/13/23 H.C. Wainwright
Ocular Therapeutix price target raised to $11 from $9 at H.C. Wainwright
01/09/23 JMP Securities
Ocular Therapeutix price target lowered to $12 from $25 at JMP Securities
11/08/22 H.C. Wainwright
Ocular Therapeutix price target lowered to $9 from $10 at H.C. Wainwright
11/08/22 Raymond James
Ocular Therapeutix price target lowered to $14 from $29 at Raymond James
GTHX G1 Therapeutics
$3.34 /

-3.805 (-53.29%)

01/30/23 JPMorgan
G1 Therapeutics upgraded to Neutral into data catalysts at JPMorgan
01/30/23 JPMorgan
G1 Therapeutics upgraded to Neutral from Underweight at JPMorgan
01/04/23 EF Hutton
G1 Therapeutics initiated with a Buy at EF Hutton
01/03/23 Needham
G1 Therapeutics named as Top Pick, added to Conviction list at Needham
AXSM Axsome Therapeutics
$62.08 /

-0.9 (-1.43%)

01/30/23 Mizuho
Axsome Therapeutics price target raised to $86 from $80 at Mizuho
01/05/23 Piper Sandler
Axsome Therapeutics initiated with a Neutral at Piper Sandler
01/03/23 BTIG
Axsome Therapeutics named Top Pick for first half of 2023 at BTIG
12/23/22 BTIG
Axsome Therapeutics price target raised to $98 from $62 at BTIG
ZIM ZIM Integrated
$20.98 /

-1.485 (-6.61%)

02/13/23 Barclays
ZIM Integrated downgraded to Underweight from Equal Weight at Barclays
11/18/22 Barclays
ZIM Integrated price target lowered to $26.50 from $63 at Barclays
09/20/22 Goldman Sachs
ZIM Integrated price target lowered to $30 from $60 at Goldman Sachs
08/23/22 Citi
ZIM Integrated downgraded to Neutral from Buy at Citi
TEVA Teva
$10.30 /

+0.04 (+0.39%)

02/09/23 Barclays
Teva price target raised to $14 from $13 at Barclays
01/23/23 Piper Sandler
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
01/19/23 Jefferies
Teva downgraded to Hold from Buy at Jefferies
01/06/23 Northland
Alvotech named a top pick for 2023 at Northland
THS TreeHouse
$48.37 /

+0.09 (+0.19%)

08/09/22 Truist
TreeHouse price target raised to $60 from $50 at Truist
08/08/22 Stifel
TreeHouse price target raised to $45 from $38 at Stifel
06/27/22 Stifel
TreeHouse meal prep sale could bring higher multiple, says Stifel
05/23/22 Truist
TreeHouse upgraded to Buy from Hold at Truist
CHKP Check Point
$128.32 /

+1.09 (+0.86%)

02/14/23 Citi
Check Point price target lowered to $129 from $130 at Citi
02/14/23 Goldman Sachs
Check Point initiated with a Buy at Goldman Sachs
02/13/23 FBN Securities
Check Point price target lowered to $150 from $155 at FBN Securities
02/09/23 Loop Capital
Fortinet price target raised to $80 from $66 at Loop Capital
SHC Sotera Health
$16.91 /

+0.11 (+0.65%)

01/23/23 JPMorgan
Sotera Health upgraded to Neutral from Underweight at JPMorgan
01/10/23 Wolfe Research
Sotera Health upgraded to Outperform at Wolfe Research after Illinois settlement
01/10/23 Wolfe Research
Sotera Health upgraded to Outperform from Peer Perform at Wolfe Research
01/10/23 Barclays
Sotera Health double-upgraded to Overweight from Underweight at Barclays
IAA IAA
$43.80 /

+0.825 (+1.92%)

01/24/23 Raymond James
Ritchie Bros. price target raised to $60 from $55 at Raymond James
01/24/23 Baird
Ritchie Bros. price target raised to $66 from $62 at Baird
01/05/23 Baird
IAA downgraded to Neutral from Outperform at Baird
12/05/22 Scotiabank
Ritchie Bros. upgraded to Outperform at Scotiabank after deal-driven pullback
RBA Ritchie Bros.
$64.17 /

+1.13 (+1.79%)

INTC Intel
$28.54 /

+0.735 (+2.64%)

02/13/23 Credit Suisse
Buyback rule tied to CHIPS Act would be 'significant' for TI, says Credit Suisse
02/13/23 Citi
January notebook shipments above expectations, says Citi
02/01/23 Morgan Stanley
AMD's softer outlook 'still could be a relief' after Intel, says Morgan Stanley
02/01/23 Credit Suisse
AMD price target raised to $96 from $90 at Credit Suisse
IBM IBM
$137.34 /

+1.73 (+1.28%)

02/06/23 Edward Jones
IBM downgraded to Hold from Buy at Edward Jones
01/31/23 Evercore ISI
IBM removed from 'Tactical Outperform' list at Evercore ISI
01/26/23 BMO Capital
IBM price target raised to $155 from $148 at BMO Capital
01/26/23 Morgan Stanley
IBM price target lowered to $143 from $148 at Morgan Stanley
QCOM Qualcomm
$130.79 /

+1.88 (+1.46%)

02/05/23 Citi
Qualcomm price target raised to $132 from $105 at Citi
02/03/23 BofA
Qualcomm expectations have likely reached trough, says BofA
02/03/23 TD Cowen
Qualcomm price target lowered to $155 from $165 at Cowen
02/03/23 Wells Fargo
Qualcomm price target raised to $130 from $105 at Wells Fargo
TXN Texas Instruments
$176.72 /

+0.97 (+0.55%)

02/03/23 Susquehanna
Texas Instruments price target raised to $210 from $205 at Susquehanna
02/02/23 Evercore ISI
Evercore ISI sees few surprises as TI outlines plans to support growth
01/25/23 BMO Capital
Texas Instruments price target raised to $215 from $195 at BMO Capital
AVGO Broadcom
$601.20 /

+6.825 (+1.15%)

02/07/23 UBS
VMware price target raised to $147 from $131 at UBS
01/23/23 Truist
Broadcom price target lowered to $659 from $662 at Truist
01/11/23 KeyBanc
KeyBanc says iPhone survey shows supply partial recovery, some shortages remain
01/10/23 Piper Sandler
Piper Sandler sees no strategic reason for Apple to insource Wi-Fi combo chip
GFS GlobalFoundries
$66.11 /

+1.525 (+2.36%)

01/23/23 Loop Capital
GlobalFoundries initiated with a Buy at Loop Capital
12/14/22 Deutsche Bank
GlobalFoundries price target raised to $70 from $67 at Deutsche Bank
11/15/22 Credit Suisse
GlobalFoundries assumed with an Outperform at Credit Suisse
ZIM ZIM Integrated
$20.98 /

-1.485 (-6.61%)

Z Zillow
$44.84 /

+1.83 (+4.25%)

WISH ContextLogic
/

+

TXN Texas Instruments
$176.72 /

+0.97 (+0.55%)

TWLO Twilio
$61.32 /

+1.24 (+2.06%)

THS TreeHouse
$48.37 /

+0.09 (+0.19%)

TEVA Teva
$10.30 /

+0.04 (+0.39%)

TDC Teradata
$39.54 /

+5.3 (+15.48%)

SHC Sotera Health
$16.91 /

+0.11 (+0.65%)

RKT Rocket Companies
$8.87 /

+0.065 (+0.74%)

RBA Ritchie Bros.
$64.17 /

+1.13 (+1.79%)

QCOM Qualcomm
$130.79 /

+1.88 (+1.46%)

OKTA Okta
$75.48 /

-0.88 (-1.15%)

OCUL Ocular Therapeutix
$5.23 /

+1.355 (+34.97%)

MSFT Microsoft
$271.21 /

+8.09 (+3.07%)

MNDY Monday.com
$145.43 /

+13.78 (+10.47%)

META Meta Platforms
$179.41 /

+5.29 (+3.04%)

MANU Manchester United
$23.59 /

+0.09 (+0.38%)

INTC Intel
$28.54 /

+0.735 (+2.64%)

IBM IBM
$137.34 /

+1.73 (+1.28%)

IAA IAA
$43.80 /

+0.825 (+1.92%)

GTHX G1 Therapeutics
$3.34 /

-3.805 (-53.29%)

GFS GlobalFoundries
$66.11 /

+1.525 (+2.36%)

FSLY Fastly
$12.61 /

+2.735 (+27.71%)

FIVE Five Below
$207.01 /

+5.27 (+2.61%)

FIS FIS
$66.02 /

-9.455 (-12.53%)

CHKP Check Point
$128.32 /

+1.09 (+0.86%)

CAT Caterpillar
$248.15 /

+0.53 (+0.21%)

AXSM Axsome Therapeutics
$62.08 /

-0.9 (-1.43%)

AVGO Broadcom
$601.20 /

+6.825 (+1.15%)

  • 18
    Nov
Z Zillow
$44.84 /

+1.83 (+4.25%)

WISH ContextLogic
/

+

TXN Texas Instruments
$176.72 /

+0.97 (+0.55%)

TWLO Twilio
$61.32 /

+1.24 (+2.06%)

TEVA Teva
$10.30 /

+0.04 (+0.39%)

TDC Teradata
$39.54 /

+5.3 (+15.48%)

SHC Sotera Health
$16.91 /

+0.11 (+0.65%)

SFTBY SoftBank Group
$22.15 /

-0.05 (-0.23%)

QCOM Qualcomm
$130.79 /

+1.88 (+1.46%)

OKTA Okta
$75.48 /

-0.88 (-1.15%)

MSFT Microsoft
$271.21 /

+8.09 (+3.07%)

META Meta Platforms
$179.41 /

+5.29 (+3.04%)

MANU Manchester United
$23.59 /

+0.09 (+0.38%)

INTC Intel
$28.54 /

+0.735 (+2.64%)

IBM IBM
$137.34 /

+1.73 (+1.28%)

FIS FIS
$66.02 /

-9.455 (-12.53%)

CHKP Check Point
$128.32 /

+1.09 (+0.86%)

CAT Caterpillar
$248.15 /

+0.53 (+0.21%)

AVGO Broadcom
$601.20 /

+6.825 (+1.15%)

ZIM ZIM Integrated
$20.98 /

-1.485 (-6.61%)

Z Zillow
$44.84 /

+1.83 (+4.25%)

TXN Texas Instruments
$176.72 /

+0.97 (+0.55%)

TWLO Twilio
$61.32 /

+1.24 (+2.06%)

THS TreeHouse
$48.37 /

+0.09 (+0.19%)

TEVA Teva
$10.30 /

+0.04 (+0.39%)

SHC Sotera Health
$16.91 /

+0.11 (+0.65%)

SFTBY SoftBank Group
$22.15 /

-0.05 (-0.23%)

RKT Rocket Companies
$8.87 /

+0.065 (+0.74%)

QCOM Qualcomm
$130.79 /

+1.88 (+1.46%)

OKTA Okta
$75.48 /

-0.88 (-1.15%)

OCUL Ocular Therapeutix
$5.23 /

+1.355 (+34.97%)

MSFT Microsoft
$271.21 /

+8.09 (+3.07%)

MNDY Monday.com
$145.43 /

+13.78 (+10.47%)

META Meta Platforms
$179.41 /

+5.29 (+3.04%)

MANU Manchester United
$23.59 /

+0.09 (+0.38%)

INTC Intel
$28.54 /

+0.735 (+2.64%)

IBM IBM
$137.34 /

+1.73 (+1.28%)

IAA IAA
$43.80 /

+0.825 (+1.92%)

GFS GlobalFoundries
$66.11 /

+1.525 (+2.36%)

FSLY Fastly
$12.61 /

+2.735 (+27.71%)

FIVE Five Below
$207.01 /

+5.27 (+2.61%)

FIS FIS
$66.02 /

-9.455 (-12.53%)

CHKP Check Point
$128.32 /

+1.09 (+0.86%)

CAT Caterpillar
$248.15 /

+0.53 (+0.21%)

AXSM Axsome Therapeutics
$62.08 /

-0.9 (-1.43%)

AVGO Broadcom
$601.20 /

+6.825 (+1.15%)

ZIM ZIM Integrated
$20.98 /

-1.485 (-6.61%)

Z Zillow
$44.84 /

+1.83 (+4.25%)

WISH ContextLogic
/

+

TXN Texas Instruments
$176.72 /

+0.97 (+0.55%)

TWLO Twilio
$61.32 /

+1.24 (+2.06%)

TEVA Teva
$10.30 /

+0.04 (+0.39%)

RKT Rocket Companies
$8.87 /

+0.065 (+0.74%)

RBA Ritchie Bros.
$64.17 /

+1.13 (+1.79%)

QCOM Qualcomm
$130.79 /

+1.88 (+1.46%)

OKTA Okta
$75.48 /

-0.88 (-1.15%)

MSFT Microsoft
$271.21 /

+8.09 (+3.07%)

MNDY Monday.com
$145.43 /

+13.78 (+10.47%)

META Meta Platforms
$179.41 /

+5.29 (+3.04%)

MANU Manchester United
$23.59 /

+0.09 (+0.38%)

INTC Intel
$28.54 /

+0.735 (+2.64%)

IBM IBM
$137.34 /

+1.73 (+1.28%)

GFS GlobalFoundries
$66.11 /

+1.525 (+2.36%)

FSLY Fastly
$12.61 /

+2.735 (+27.71%)

FIVE Five Below
$207.01 /

+5.27 (+2.61%)

FIS FIS
$66.02 /

-9.455 (-12.53%)

CAT Caterpillar
$248.15 /

+0.53 (+0.21%)

AXSM Axsome Therapeutics
$62.08 /

-0.9 (-1.43%)

AVGO Broadcom
$601.20 /

+6.825 (+1.15%)

Hot Stocks
Axsome received Paragraph IV certification notice on Auvelity ANDA from Teva » 13:38
02/13/23
02/13
13:38
02/13/23
13:38
AXSM

Axsome Therapeutics

$61.86 /

-1.12 (-1.78%)

, TEVA

Teva

$10.25 /

-0.015 (-0.15%)

In a regulatory filing…

In a regulatory filing earlier, Axsome Therapeutics (AXSM) disclosed that on February 10, the company received a Paragraph IV Certification Notice Letter from Teva Pharmaceuticals (TEVA), providing notification to the company that Teva has submitted an Abbreviated New Drug Application, or "ANDA," to the U.S. Food and Drug Administration seeking approval to manufacture, use, or sell a generic version of Auvelity, or dextromethorphan HBr-bupropion HCl. "In the Notice Letter, Teva alleges that four of the patents listed in the FDA Orange Book for Auvelity, U.S. Patent Numbers 10,780,064; 10,925,842; 10,940,124; and 10,966,942, each of which expires in 2040, are invalid, unenforceable, or will not be infringed by Teva's manufacture, use, or sale of the generic product described in its ANDA submission. The Paragraph IV Certification does not challenge any of the remaining Orange Book listed patents for Auvelity which have expirations out to 2034," Axsome stated in the filing.

ShowHide Related Items >><<
TEVA Teva
$10.25 /

-0.015 (-0.15%)

AXSM Axsome Therapeutics
$61.86 /

-1.12 (-1.78%)

AXSM Axsome Therapeutics
$61.86 /

-1.12 (-1.78%)

01/30/23 Mizuho
Axsome Therapeutics price target raised to $86 from $80 at Mizuho
01/05/23 Piper Sandler
Axsome Therapeutics initiated with a Neutral at Piper Sandler
01/03/23 BTIG
Axsome Therapeutics named Top Pick for first half of 2023 at BTIG
12/23/22 BTIG
Axsome Therapeutics price target raised to $98 from $62 at BTIG
TEVA Teva
$10.25 /

-0.015 (-0.15%)

02/09/23 Barclays
Teva price target raised to $14 from $13 at Barclays
01/23/23 Piper Sandler
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
01/19/23 Jefferies
Teva downgraded to Hold from Buy at Jefferies
01/06/23 Northland
Alvotech named a top pick for 2023 at Northland
TEVA Teva
$10.25 /

-0.015 (-0.15%)

AXSM Axsome Therapeutics
$61.86 /

-1.12 (-1.78%)

TEVA Teva
$10.25 /

-0.015 (-0.15%)

TEVA Teva
$10.25 /

-0.015 (-0.15%)

AXSM Axsome Therapeutics
$61.86 /

-1.12 (-1.78%)

TEVA Teva
$10.25 /

-0.015 (-0.15%)

AXSM Axsome Therapeutics
$61.86 /

-1.12 (-1.78%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.